91 related articles for article (PubMed ID: 12668857)
1. Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology.
Reginelli JP; Bhatt DL
J Invasive Cardiol; 2002 Dec; 14 Suppl E():2E-10E; quiz 11E. PubMed ID: 12668857
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
3. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
Goldschmidt-Clermont PJ
J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
[No Abstract] [Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
Lincoff AM; Topol EJ
Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
[No Abstract] [Full Text] [Related]
5. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
[TBL] [Abstract][Full Text] [Related]
6. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
7. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
Rasti M; Blostein M
Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
[TBL] [Abstract][Full Text] [Related]
8. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
Gum PA; Lincoff AM
Int J Clin Pract; 2003; 57(1):43-8. PubMed ID: 12587942
[TBL] [Abstract][Full Text] [Related]
9. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited.
Tang WH; Lincoff AM
Circulation; 2004 Dec; 110(24):3618-20. PubMed ID: 15596556
[No Abstract] [Full Text] [Related]
10. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
Talley JD
J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
[No Abstract] [Full Text] [Related]
11. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Popma JJ; Satler LF
J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
[TBL] [Abstract][Full Text] [Related]
12. Late outcomes after intervention of vein grafts in diabetics with abciximab use.
Applegate RJ; Upadhya B; Little WC; Xenakis M; Gandhi SK; Baki TT; Kahl FR; Kutcher MA
Int J Cardiol; 2006 Jul; 111(1):136-41. PubMed ID: 16226815
[TBL] [Abstract][Full Text] [Related]
13. [Percutaneous coronary intervention in diabetic patients].
Lablanche JM; Rosey G; Zoubidi M; Sudre A
Bull Acad Natl Med; 2005 Feb; 189(2):249-56. PubMed ID: 16114856
[TBL] [Abstract][Full Text] [Related]
14. Interventional therapy for coronary artery disease.
Shah PB; Lilly CM
Am J Respir Crit Care Med; 2002 Sep; 166(6):791-6. PubMed ID: 12231486
[No Abstract] [Full Text] [Related]
15. Unexpected mortality reduction with abciximab for in-stent restenosis.
Mukherjee D; Reginelli JP; Moliterno DJ; Yadav JS; Schneider JP; Raymond R; Whitlow PL; Franco I; Topol EJ; Ellis SG
J Invasive Cardiol; 2000 Nov; 12(11):540-4. PubMed ID: 11060563
[TBL] [Abstract][Full Text] [Related]
16. Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
Lepor NE
Rev Cardiovasc Med; 2006; 7 Suppl 4():S38-48. PubMed ID: 17224890
[TBL] [Abstract][Full Text] [Related]
17. Abciximab provides cost-effective survival advantage in high-volume interventional practice.
Kereiakes DJ; Obenchain RL; Barber BL; Smith A; McDonald M; Broderick TM; Runyon JP; Shimshak TM; Schneider JF; Hattemer CR; Roth EM; Whang DD; Cocks D; Abbottsmith CW
Am Heart J; 2000 Oct; 140(4):603-10. PubMed ID: 11011333
[TBL] [Abstract][Full Text] [Related]
18. Use of abciximab in interventional cardiology.
Chronos N; Vahanian A; Betriu A; Emanuelsson H; Goldberg S; Gulba D; van Hout BA
Eur Heart J; 1998 Apr; 19 Suppl D():D31-9. PubMed ID: 9597520
[TBL] [Abstract][Full Text] [Related]
19. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
Shishehbor MH; Topol EJ; Mukherjee D; Hu T; Cohen DJ; Stone GW; McClure R; Roffi M; Moliterno DJ;
Am J Cardiol; 2006 Jun; 97(11):1585-90. PubMed ID: 16728219
[TBL] [Abstract][Full Text] [Related]
20. Inflammation as a therapeutic target: a unique role for abciximab.
Kereiakes DJ
Am Heart J; 2003 Oct; 146(4 Suppl):S1-4. PubMed ID: 14564299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
